Cargando…
Metformin – a new approach
Metformin is a widely used biguanide drug recommended as a first-line antidiabetic for type 2 diabetes. Currently, metformin is used not only in the treatment of diabetes but also in other diseases. Some studies have shown that metformin causes weight loss in insulin-sensitive and insulin-resistant...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214935/ https://www.ncbi.nlm.nih.gov/pubmed/34514769 http://dx.doi.org/10.5114/pedm.2021.107166 |
_version_ | 1785047944489074688 |
---|---|
author | Cwynar-Zając, Łucja |
author_facet | Cwynar-Zając, Łucja |
author_sort | Cwynar-Zając, Łucja |
collection | PubMed |
description | Metformin is a widely used biguanide drug recommended as a first-line antidiabetic for type 2 diabetes. Currently, metformin is used not only in the treatment of diabetes but also in other diseases. Some studies have shown that metformin causes weight loss in insulin-sensitive and insulin-resistant overweight and obese patients. Metformin is an effective and safe option for women with gestational diabetes and type 2 diabetes in pregnancy, and it may also increase the ovulation rate in patients with polycystic ovary syndrome (PCOS). Longer survival times have been observed in cancer patients using metformin. Metformin has been shown to significantly correlate with lower mortality in obese or type 2 diabetic women hospitalized for COVID-19. It also has a protective effect on the development and progression of many types of cancer. The mechanisms of action of metformin are complex and still not fully understood. Metformin has been shown to act through both AMP-activated protein kinase (AMPK)-dependent mechanisms and AMPK-independent mechanisms. This paper presents the benefits of using metformin in the treatment of various diseases. |
format | Online Article Text |
id | pubmed-10214935 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-102149352023-06-05 Metformin – a new approach Cwynar-Zając, Łucja Pediatr Endocrinol Diabetes Metab Review paper | Praca poglądowa Metformin is a widely used biguanide drug recommended as a first-line antidiabetic for type 2 diabetes. Currently, metformin is used not only in the treatment of diabetes but also in other diseases. Some studies have shown that metformin causes weight loss in insulin-sensitive and insulin-resistant overweight and obese patients. Metformin is an effective and safe option for women with gestational diabetes and type 2 diabetes in pregnancy, and it may also increase the ovulation rate in patients with polycystic ovary syndrome (PCOS). Longer survival times have been observed in cancer patients using metformin. Metformin has been shown to significantly correlate with lower mortality in obese or type 2 diabetic women hospitalized for COVID-19. It also has a protective effect on the development and progression of many types of cancer. The mechanisms of action of metformin are complex and still not fully understood. Metformin has been shown to act through both AMP-activated protein kinase (AMPK)-dependent mechanisms and AMPK-independent mechanisms. This paper presents the benefits of using metformin in the treatment of various diseases. Termedia Publishing House 2021-06-20 2021-06 /pmc/articles/PMC10214935/ /pubmed/34514769 http://dx.doi.org/10.5114/pedm.2021.107166 Text en Copyright © Polish Society of Pediatric Endocrinology and Diabetes https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), allowing third parties to download and share its works but not commercially purposes or to create derivative works. |
spellingShingle | Review paper | Praca poglądowa Cwynar-Zając, Łucja Metformin – a new approach |
title | Metformin – a new approach |
title_full | Metformin – a new approach |
title_fullStr | Metformin – a new approach |
title_full_unstemmed | Metformin – a new approach |
title_short | Metformin – a new approach |
title_sort | metformin – a new approach |
topic | Review paper | Praca poglądowa |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214935/ https://www.ncbi.nlm.nih.gov/pubmed/34514769 http://dx.doi.org/10.5114/pedm.2021.107166 |
work_keys_str_mv | AT cwynarzajacłucja metforminanewapproach |